There were 1,637 press releases posted in the last 24 hours and 468,213 in the last 365 days.

Insights on the Tuberculosis Diagnosis and Treatment Global Market to 2028 - Due to the Various Technological Advancement New Diagnostics Solutions are Available

DUBLIN, Sept. 22, 2022 /PRNewswire/ -- The "Global Tuberculosis Diagnosis and Treatment Market 2022-2028" report has been added to's offering.

The global tuberculosis diagnosis and treatment market is anticipated to grow at a substantial CAGR of 6.1% during the forecast period. The increasing technological advancement in TB leads to considerable growth in the market. Due to the various technological advancement, new diagnostics solutions are made available to diagnose these diseases which also provides accuracy and speed.

The WHO-recommended molecular diagnostic tests are LPAs and Xpert MTB/RIF and the initial diagnosis of TB is made by rapid molecular tests (e.g. Xpert MTB/RIF) and not by conventional microscopy methods. Light-emitting diode fluorescence microscopy is the recommended method for microscopy at all levels of laboratory. Some of these WHO-endorsed tests can detect mycobacterial gene mutations associated with anti-TB drug resistance, allowing clinicians to tailor effective TB treatment and directly boosting the market.

For instance in 2022, WHO announced a new class of tests to diagnose TB infection named Tuberculosis antigen-based skin tests (TBST).These tests represent an alternative to tuberculin skin test (TST) and Interferon-Gamma Release Assays (IGRAs).

The global tuberculosis diagnosis and treatment market is segmented based on technology, products, application and end-user. Based on technology the market is sub-divided into cell-based, and bead-based. Based on products the market is bifurcated into reagents and consumables, components, platforms, services, software, and accessories. Based on application the market is sub-segmented into research and clinical application, and diagnostic application. Based on end-user, the market is sub-segmented into hospitals, research institutes, clinical testing labs, and others.

The hospital segment is anticipated to grow at the fastest rate, as hospitals assist the patients to take medical assistance under the observation of experienced surgeons. The increasing number of cancer patients along with growing awareness regarding the various benefits and facilities provided in hospitals is considered a prime factor that is supporting the growth of the hospital segment.

Geographically market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America dominates the market and is expected to continue its presence over the forecast period. The growth can be attributed to the different factors such as different initiatives by governments and non-profit organizations. According to UNDPby 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases. So this will boost the market for the diagnostic market.

The major companies serving the global tuberculosis diagnosis and treatment market are Cepheid Inc., Eiken Chemical Co. Ltd., Hain Lifescience GmbH and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in 2021 Hain Lifescience GmbH innovated a direct test for the advanced TB laboratory named FluoroTypes based on the innovative Fluoro Type technology enabling the direct detection of M. tuberculosis complex from direct sample material such as decontaminated pulmonary and, depending on the test, extrapulmonary patient samples

The Report Covers

  • Comprehensive research methodology of the global tuberculosis diagnosis and treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global tuberculosis diagnosis and treatment market.
  • Insights about market determinants that are stimulating the global tuberculosis diagnosis and treatment market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion

3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Otsuka Pharmaceuticals Co. Ltd. Overview Financial Analysis SWOT Analysis Recent Developments
3.1.2. Johnson & Johnson Services Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.1.3. Abbott Laboratories, Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.1.4. Becton, Dickinson and Co. Overview Financial Analysis SWOT Analysis Recent Developments
3.1.5. Thermo Fisher Scientific, Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players

4. Market Segmentation
4.1. Global Tuberculosis diagnosis and treatment Market, by Diagnosis
4.1.1. Laboratory Testing
4.1.2. Nucleic Acid Tests
4.1.3. Radiography
4.1.4. Drug Susceptibility Test
4.1.5. Other Tests
4.2. Global Tuberculosis diagnosis and treatment Market, by Drugs
4.2.1. First Line Drugs
4.2.2. Second Line Drugs
4.3. Global Tuberculosis diagnosis and treatment Market, by End-user
4.3.1. Hospitals& Clinics
4.3.2. Government & Non-Government Organizations
4.3.3. Others

5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles
6.1. Abbott Laboratories Inc.
6.2. Akonni Biosystems, Inc.
6.3. Becton Dickinson and Co.
6.4. Biochemical and Synthetic Products Pvt Ltd
6.5. Biomerieux SA
6.6. Cepheid Inc.
6.7. Eiken Chemical Co. Ltd.
6.8. EpistemLtd.
6.9. F. Hoffmann-LA Roche AG
6.10. GlaxoSmithKline PLC
6.11. Hain Lifescience GmbH
6.12. HologicInc.
6.13. Johnson & Johnson Services, Inc.
6.14. LabatecPharma SA
6.15. Lupin Pharmaceuticals Inc.
6.16. Novartis AG
6.17. Otsuka Pharmaceutical Co. Ltd.
6.18. PerkinElmer Inc.
6.19. QiagenGmbH
6.20. Sanofi SA
6.21. Thermo Fisher Scientific, Inc.

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager   

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716 


View original content:

SOURCE Research and Markets